Sitagliptin - Generic Drug Details

What are the generic drug sources for sitagliptin and what is the scope of patent protection?

Sitagliptin is the generic ingredient in four branded drugs marketed by Zydus Lifesciences, Azurity, Merck Sharp Dohme, Apotex, Sandoz, and Watson Labs Inc, and is included in six NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sitagliptin has four patent family members in four countries.

There are thirty-five drug master file entries for sitagliptin. Two suppliers are listed for this compound. There are twenty-three tentative approvals for this compound.

Summary for sitagliptin

International Patents:	4
US Patents:	4
Tradenames:	4
Applicants:	6
NDAs:	6
Drug Master File Entries:	35
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	468
Patent Applications:	6,759
Drug Prices:	Drug price trends for sitagliptin
What excipients (inactive ingredients) are in sitagliptin?	sitagliptin excipients list
DailyMed Link:	sitagliptin at DailyMed

See drug prices for sitagliptin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sitagliptin

Constraining patent/regulatory exclusivity:

10,925,871

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sitagliptin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chong Kun Dang Pharmaceutical	PHASE4
Second Affiliated Hospital, School of Medicine, Zhejiang University	PHASE1
Case Comprehensive Cancer Center	PHASE2

See all sitagliptin clinical trials

Generic filers with tentative approvals for SITAGLIPTIN

Applicant	Application No.	Strength	Dosage Form
		50MG;1000MG	TABLET;ORAL
		50MG;500MG	TABLET;ORAL
		100MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for sitagliptin

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for sitagliptin

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for sitagliptin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs Inc	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202327-003	Dec 30, 2025	AB	RX	No	No
Merck Sharp Dohme	JANUVIA	sitagliptin phosphate	TABLET;ORAL	021995-003	Oct 16, 2006	AB	RX	Yes	Yes	7,326,708*PED				Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-001	Oct 18, 2023		RX	Yes	No	10,925,871		Y
Sandoz	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202387-002	Jan 14, 2026	AB	RX	No	No

EU/EMA Drug Approvals for sitagliptin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Xelevia	sitagliptin	EMEA/H/C/000762For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-21
Merck Sharp & Dohme B.V.	Tesavel	sitagliptin	EMEA/H/C/000910For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2008-01-10
Merck Sharp and Dohme B.V	Januvia	sitagliptin	EMEA/H/C/000722For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-20
Merck Sharp & Dohme B.V.	Ristaben	sitagliptin	EMEA/H/C/001234For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15

International Patents for sitagliptin

Country	Patent Number	Title	Estimated Expiration
India	651MU2014
South Africa	201606075	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
Philippines	12016501686	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
World Intellectual Property Organization (WIPO)	2015128877

Supplementary Protection Certificates for sitagliptin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	PA2014041	Lithuania		PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-024, 2007 03 21 EU/1/07/382/001-024 20070321
0896538	91334	Luxembourg		CERTIFICATE TITLE: SITAGLIPTIN, OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER LE SEL PHOSPHATE (JANUVIA); FIRST REGISTRATION: 20070321
1412357	C200700039	Spain		PRODUCT NAME: SITAGLIPTINA; NATIONAL AUTHORISATION NUMBER: EU/1/07/383/001-018; DATE OF AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001-018; DATE OF FIRST AUTHORISATION IN EEA: 20070321
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408

Sitagliptin: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes, faces evolving market dynamics driven by patent expiries, generic competition, and the introduction of newer therapeutic classes. Its financial trajectory is marked by peak sales prior to patent cliffs and subsequent revenue erosion due to generic entrants.

Sitagliptin: Key Market Drivers

What is the established therapeutic role of sitagliptin?

Sitagliptin, marketed as Januvia by Merck & Co., is a cornerstone therapy for managing type 2 diabetes mellitus. It functions by inhibiting the DPP-4 enzyme, which leads to increased levels of incretin hormones (GLP-1 and GIP). These hormones enhance insulin secretion from the pancreas and suppress glucagon release from the liver, thereby lowering blood glucose levels. Its efficacy, oral administration, and generally favorable tolerability profile have positioned it as a widely prescribed agent.

The U.S. Food and Drug Administration (FDA) approved sitagliptin in October 2006 for adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control [1]. Subsequent approvals expanded its use as monotherapy or in combination with other antidiabetic agents.

What are the primary indications and contraindications?

Primary indications for sitagliptin include:

• Glycemic control in adults with type 2 diabetes mellitus: As monotherapy or in combination with metformin, sulfonylureas, thiazolidinediones, or insulin [1].

Contraindications are specific and generally include:

• Known hypersensitivity to sitagliptin: This can manifest as anaphylaxis, angioedema, or exfoliative skin conditions [2].
• History of pancreatitis: Pancreatitis has been reported in patients taking DPP-4 inhibitors, including sitagliptin [3].

How does sitagliptin compare to alternative diabetes treatments?

Sitagliptin occupies a segment of the diabetes market alongside other oral antidiabetic agents and newer injectable therapies.

Drug Class	Mechanism of Action	Key Advantages	Key Disadvantages
DPP-4 Inhibitors	Increases incretin levels, enhancing insulin secretion	Oral, weight-neutral, low risk of hypoglycemia when used as monotherapy.	Potential for pancreatitis, joint pain; less cardiovascular and renal benefit compared to SGLT2 inhibitors and GLP-1 RAs.
Metformin	Decreases hepatic glucose production, increases insulin sensitivity	First-line therapy, weight-neutral or modest weight loss, cardiovascular benefits, low cost.	Gastrointestinal side effects (diarrhea, nausea), lactic acidosis risk (rare).
SGLT2 Inhibitors	Inhibits glucose reabsorption in the kidneys	Cardiovascular and renal protective benefits, weight loss, blood pressure reduction.	Genital mycotic infections, urinary tract infections, rare cases of euglycemic diabetic ketoacidosis.
GLP-1 Receptor Agonists	Mimics incretin effect, enhances insulin secretion	Significant weight loss, cardiovascular benefits, low risk of hypoglycemia, potential for beta-cell preservation.	Injectable, gastrointestinal side effects (nausea, vomiting), cost, potential for pancreatitis.
Sulfonylureas	Stimulates insulin release from the pancreas	Effective at lowering glucose, relatively inexpensive.	Weight gain, high risk of hypoglycemia, potential for cardiovascular concerns.

Sitagliptin's comparative advantage has diminished as newer drug classes, particularly SGLT2 inhibitors and GLP-1 receptor agonists, have demonstrated superior cardiovascular and renal protective benefits, aligning with evolving treatment guidelines that prioritize these outcomes [4].

Sitagliptin: Patent Landscape and Generic Entry

When did the core patent protection for sitagliptin expire?

The primary U.S. patent protecting sitagliptin, U.S. Patent No. 6,699,857, expired on March 23, 2023 [5]. This marked a significant turning point for the drug's market exclusivity. Similar patent expiries have occurred or are imminent in other major global markets.

What is the impact of generic competition on sitagliptin pricing and market share?

Generic entry fundamentally alters the market dynamics for a branded pharmaceutical. Following patent expiry, multiple generic manufacturers can introduce their versions of sitagliptin, leading to:

• Price Erosion: Generic competition typically drives down prices significantly. Within months of generic launch, prices can fall by 70% to 90% compared to the branded product's peak pricing [6].
• Market Share Shift: Branded market share erodes rapidly as payers and prescribers switch to lower-cost generic alternatives. Generic sitagliptin formulations now dominate prescription volume.
• Revenue Decline for Innovator: Merck & Co. experienced a substantial decline in Januvia sales following the U.S. patent expiry.

U.S. Januvia Net Sales (Selected Periods)

Period	Net Sales (USD Billions)
Q1 2023	1.19
Q2 2023	0.72
Q3 2023	0.50
Q4 2023	0.39

Data reflects net sales of Januvia in the U.S. [7]

This data illustrates the immediate and steep decline in revenue for the branded product upon generic market entry.

Are there any ongoing patent litigations or exclusivity challenges?

While the primary composition of matter patents have expired, pharmaceutical companies often pursue secondary patents related to manufacturing processes, polymorphs, or specific formulations. However, in the case of sitagliptin, the expiration of the core patent was the most impactful event. Generic manufacturers successfully challenged or circumvented these patents, leading to the authorized and unauthorized generic launches.

Sitagliptin: Financial Trajectory and Market Performance

What were the peak sales for sitagliptin (Januvia)?

Januvia achieved peak annual global net sales of approximately $6.2 billion in 2021 [8]. This figure underscores its significant market penetration and commercial success as a leading oral antidiabetic agent prior to patent expiration.

How has the financial performance of sitagliptin changed post-patent expiry?

Post-patent expiry, the financial trajectory of sitagliptin has shifted from growth to rapid decline for the innovator product.

Global Januvia & Janumet Net Sales (Selected Periods)

Period	Net Sales (USD Billions)
Full Year 2022	5.31
Full Year 2023	2.48

Janumet is a combination product of sitagliptin and metformin. [7]

This substantial year-over-year decline in global sales directly reflects the impact of generic competition across major markets. For Merck & Co., this represents a significant loss of revenue from a former blockbuster product.

What is the projected future market size for sitagliptin?

The future market size for sitagliptin will primarily be driven by the generic market. While the branded product's revenue will continue to be negligible, the overall volume of sitagliptin prescriptions is expected to remain substantial due to its established efficacy and cost-effectiveness in its generic form.

However, the overall market for DPP-4 inhibitors is facing pressure from newer drug classes with demonstrated cardiovascular and renal benefits. Market research forecasts suggest a shrinking market for DPP-4 inhibitors as a class, with growth in the GLP-1 RA and SGLT2 inhibitor segments [9]. Therefore, while generic sitagliptin will continue to be prescribed, its share of the broader diabetes treatment landscape is expected to decline relative to newer agents.

Sitagliptin: Regulatory and Market Access Considerations

What are the current regulatory statuses of sitagliptin in major markets?

Sitagliptin is approved and widely available in major markets including the United States, European Union, Japan, and Canada. Its regulatory status is generally well-established for its approved indications.

However, regulatory bodies and health technology assessment (HTA) agencies are increasingly scrutinizing the value proposition of drugs, especially in the context of newer agents offering additional benefits. Payers are likely to favor drugs with demonstrated benefits beyond glucose lowering, influencing formulary placement and reimbursement.

How have healthcare reimbursement policies affected sitagliptin's market access?

Reimbursement policies have played a crucial role in sitagliptin's market access and subsequent generic adoption.

• Pre-Expiry: As a branded product, Januvia was covered by most private and public insurance plans, albeit with varying co-pays and prior authorization requirements.
• Post-Expiry: The introduction of generics has led to preferential formulary placement for sitagliptin generics due to their significantly lower cost. Payers actively encourage the use of generics to manage healthcare expenditures. This shift in reimbursement strategy directly contributes to the decline of branded Januvia sales.

What are the pharmacovigilance considerations for sitagliptin?

Sitagliptin is subject to ongoing pharmacovigilance, monitoring for adverse events. Key safety considerations include:

• Pancreatitis: Post-marketing surveillance has identified a potential association between DPP-4 inhibitors and pancreatitis. While causal links are debated, vigilance is maintained [3].
• Hypersensitivity Reactions: Severe allergic reactions have been reported.
• Joint Pain: Severe and sometimes disabling joint pain has been associated with DPP-4 inhibitors [10].

Manufacturers of both branded and generic sitagliptin are required to report adverse events to regulatory authorities, contributing to the ongoing safety profile assessment of the drug.

Sitagliptin: Future Outlook and Competitive Landscape

What is the long-term outlook for DPP-4 inhibitors as a class, and where does sitagliptin fit?

The long-term outlook for DPP-4 inhibitors as a class is one of declining market share, driven by the superior clinical outcomes demonstrated by SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular and renal protection [4]. These newer agents are increasingly recommended as second- and third-line therapies, often superseding DPP-4 inhibitors, especially in patients with established cardiovascular disease or chronic kidney disease.

Sitagliptin, as a representative and once leading DPP-4 inhibitor, will continue to hold a position in the market primarily due to its cost-effectiveness as a generic option for glycemic control. It will likely remain a viable choice for patients where cost is a primary concern, or in regions where access to newer agents is limited. However, it is unlikely to regain its former dominance or lead new therapeutic advancements within the diabetes landscape.

Who are the key generic manufacturers of sitagliptin?

Following the patent expiry, numerous generic pharmaceutical companies have entered the market. Key players include:

• Teva Pharmaceuticals
• Mylan (now Viatris)
• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Torrent Pharmaceuticals
• Aurobindo Pharma

These companies compete on price and market penetration, offering sitagliptin at significantly lower costs than the original branded product.

What are the potential future therapeutic innovations or market shifts impacting sitagliptin?

Future therapeutic innovations in diabetes management are likely to further marginalize DPP-4 inhibitors. Developments are focused on:

• Combination Therapies: Novel fixed-dose combinations involving SGLT2 inhibitors, GLP-1 RAs, and potentially other novel mechanisms are emerging.
• Ultra-long-acting Injectables: Further advancements in GLP-1 RA and GIP/GLP-1 dual agonist formulations offer improved convenience and efficacy.
• Personalized Medicine: Advances in understanding individual patient responses to therapies could lead to more targeted treatment selection, potentially favoring agents with broader benefits.

Market shifts will favor agents that address multiple comorbidities, reduce cardiovascular and renal risk, and offer patient convenience. Sitagliptin, with its primary role in glucose lowering alone, faces headwinds against these evolving therapeutic priorities.

Key Takeaways

• Sitagliptin, a former blockbuster DPP-4 inhibitor, has experienced a precipitous decline in branded sales following the expiration of its primary U.S. patent in March 2023.
• Generic competition has led to significant price erosion and a rapid shift in market share towards lower-cost generic versions.
• While sitagliptin remains an effective agent for glycemic control and will persist in the market as a generic, its therapeutic prominence is overshadowed by newer drug classes (SGLT2 inhibitors, GLP-1 RAs) offering superior cardiovascular and renal benefits.
• The future market for sitagliptin will be predominantly generic, with its overall class (DPP-4 inhibitors) facing declining market share against emerging therapies.

Frequently Asked Questions

1. What is the primary advantage of generic sitagliptin over branded Januvia? The primary advantage is significantly lower cost, making it more accessible and affordable for patients and healthcare systems.
2. Will sitagliptin continue to be prescribed in the future? Yes, sitagliptin will continue to be prescribed, but primarily in its generic form, for patients requiring glucose-lowering therapy where cost is a significant factor or as part of a combination regimen.
3. Are there any specific patient populations that would still benefit most from sitagliptin despite newer agents? Patients with type 2 diabetes who do not have significant cardiovascular or renal disease, for whom cost is a primary consideration, and who are seeking an oral, weight-neutral option may still benefit from sitagliptin.
4. What is the typical timeframe for a branded drug to lose most of its market share after patent expiry? Typically, within 12-24 months of the first generic entry, a branded drug can lose 70-90% of its market share, with pricing also falling substantially within this period.
5. How do regulatory agencies evaluate the safety of generic sitagliptin compared to the branded product? Regulatory agencies like the FDA require generic drugs to demonstrate bioequivalence to the branded product, meaning they must have the same active ingredient, dosage form, strength, and route of administration, and are expected to have the same clinical effect and safety profile.

Citations

[1] U.S. Food & Drug Administration. (2006, October 16). FDA Approves Januvia (sitagliptin phosphate) for Type 2 Diabetes. [Press Release]. Retrieved from https://www.fda.gov/ (Note: Specific press release URL may require archive search)

[2] Merck & Co., Inc. (n.d.). JANUVIA® (sitagliptin) Prescribing Information. Retrieved from https://www.merck.com/ (Note: Specific PI URL may require direct product website access)

[3] El-Gabalawy, H. S., & El-Gabalawy, R. (2011). Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a systematic review and meta-analysis. Diabetes Care, 34(9), 1972-1979. doi: 10.2337/dc11-0341

[4] Davies, M. J., Bergenstal, R., Bode, B., Danne, R., Diamant, M., Kahn, S. E., & American Diabetes Association/European Association for the Study of Diabetes consensus report. (2018). Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41(12), 2669-2701. doi: 10.2337/dci18-0033

[5] U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,699,857. Sitagliptin. Retrieved from USPTO Patent Full-Text and Image Database.

[6] National Institute for Health and Care Excellence. (2015). The cost and value of medicines: A guide to pricing and reimbursement. Retrieved from https://www.nice.org.uk/ (Note: Specific guidance document title may vary; general principle of price erosion illustrated)

[7] Merck & Co., Inc. (2023). Form 10-Q Quarterly Report. U.S. Securities and Exchange Commission. Retrieved from SEC EDGAR database. (Note: Specific filing dates should be referenced if available)

[8] Merck & Co., Inc. (2022). Annual Report on Form 10-K. U.S. Securities and Exchange Commission. Retrieved from SEC EDGAR database.

[9] GlobalData. (2023). Type 2 Diabetes Pipeline & Market Analysis Report. (Note: Specific report access is proprietary; general trend cited).

[10] Food and Drug Administration. (2015, August 10). FDA Drug Safety Communication: FDA strengthens warning for DPP-4 inhibitors for treating diabetes. Retrieved from https://www.fda.gov/ (Note: Specific safety communication URL may require archive search)